A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
PHASE3CompletedINTERVENTIONAL
Enrollment
100
Participants
Timeline
Start Date
April 22, 2016
Primary Completion Date
April 13, 2017
Study Completion Date
June 29, 2017
Conditions
Chronic Hepatitis CHCVHepatitis C Virus
Interventions
DRUG
glecaprevir/pibrentasvir
Tablet; glecaprevir coformulated with pibrentasvir